Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 6,446 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Clear all

Conditions: Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: filgrastim, recombinant interleukin-11; Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Renal Transplant Rejection
Interventions: Magnetic Resonance Imaging; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Transplant Rejection, Immunosuppression
Interventions: Allosure, Immunosuppression reduction, Trugraf; Diagnostic Test · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
Interventions: Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions: LSALT peptide, Placebo; Drug
Lead sponsor: Arch Biopartners Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana

Conditions: Renal Transplantation
Interventions: Tacrolimus, Prograf®; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 42
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Kidney Transplant
Interventions: sirolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 18 more

Conditions: Immune Tolerance
Interventions: Hematopoietic cell transplantation, Total Lymphoid irradiation; Biological · Radiation
Lead sponsor: Stephan Busque; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Kidney Cancer, Renal Cell Carcinoma
Interventions: Ceevra Reveal; Device
Lead sponsor: Ceevra, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Jacksonville, Florida • New York, New York + 3 more

Conditions: Arterial Hypertension, Atrial Fibrillation
Interventions: Circumferential PV isolation, PV isolation+renal denervation; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Contrast Induced Nephropathy
Interventions: erythropoeitin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Gainesville, Florida • Chicago, Illinois • Maywood, Illinois

Conditions: Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Lupus Nephritis
Interventions: BMS-986553; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 11
States / cities: Newport Beach, California • Worcester, Massachusetts • Ann Arbor, Michigan + 7 more

Conditions: Prostate Cancer, Kidney Cancer
Interventions: High intensity approach, Low intensity approach; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Chambersburg, Pennsylvania

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Adam C Dziorny; Other
Eligibility: 30 Days to 18 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Kidney Damage
Interventions: Desmopressin; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
Interventions: Hectorol (doxercalciferol capsules), 0.5mcg; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more

Conditions: Kidney Diseases
Interventions: Control, Protein, Protein + Exercise; Dietary Supplement · Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 30 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Urbana, Illinois

Conditions: Fatigue, End Stage Renal Disease (ESRD)
Interventions: Lipidose, Placebo; Drug
Lead sponsor: Sepsicure; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Stone, Hypernatriuria
Interventions: Standard dietary counseling, Mobile app; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Gout, Hyperuricemia
Interventions: SAP-001; Drug
Lead sponsor: Shanton Pharma Pte. Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Tampa, Florida • Saint Paul, Minnesota

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo, Zigakibart; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more

Conditions: Chronic Kidney Diseases, Eye Diseases, Cardiac Disease, Surgery, Low Back Pain
Interventions: Multicomponent Physician Performance Peer-Comparison Feedback Intervention; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 5,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lupus Nephritis
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 20 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more

Search by objective public record fields.

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Multi-Parametric MRI for Renal Transplantation

Immune Monitoring to Facilitate Belatacept Monotherapy

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

Optimizing Prograf® Therapy in Renal Transplant Patients

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.

Using Virtual Reality (VR) Models for Preoperative Planning

Combined Treatment of Arterial Hypertension and Atrial Fibrillation

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

Prospective Validation of AKI Prediction

To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Intra Hemodialytic Oral Protein and Exercise (IHOPE)

Lipid Infusion in Dialysis Patients With Endotoxemia

Software Application for Low-Sodium Diet Trial (SALT)

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

Atrasentan in Patients With IgA Nephropathy

Smarter Care Virginia, Examining Low-Value Care in Virginia

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study